FindMyKOL

Gabriel Uwaifo, MD

Basic profile

Southern Illinois University School of Medicine

ORCIDOn fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionSpringfield, IL · MidwestSpecialtyEndocrinology, Diabetes & MetabolismFocusEndocrinology/Metabolic
Active KOLFindMyKOL type: RegionalLatest publication2025Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Gabriel Uwaifo is an Endocrinology/Metabolic physician affiliated with Southern Illinois University School of Medicine. OpenAlex indexes 374 publications with 11,173 citations (h-index 33).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
374publications

Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.

11,173citations

Citations across these publications.

33h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
17companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

17 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Eli Lilly
    Program year20251 paymentResearch
    $59,571
  • Eli Lilly and Company
    Program year202522 payments
    $2,852
  • Alexion Pharmaceuticals, Inc.
    Program year20251 payment
    $1,125
All 28 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    42.2%
    Biguanide (metformin)11%
    Metformin Hcl Er54%Metformin Hcl46%
    Part D≥46 patients
    GLP-1 receptor agonist10.9%
    Ozempic31%Victoza 3-Pak22%Trulicity18%Mounjaro14%Victoza 2-Pak9%Rybelsus6%
    Part D<11 patients

    + 9 more classes in this area

  • Hormonal (systemic)

    25.9%
    l-Thyroxine20.6%
    Levothyroxine Sodium80%Synthroid20%
    Part D≥115 patients
    Thyroid Hormone Synthesis Inhibitor1.4%
    Methimazole100%
    Part D<11 patients

    + 5 more classes in this area

  • Cardiovascular

    16.6%
    Statin7.7%
    Atorvastatin Calcium49%Pravastatin Sodium27%Rosuvastatin Calcium24%
    Part D≥25 patients
    ACE inhibitor3.4%
    Lisinopril100%
    Part D≥28 patients

    + 5 more classes in this area

Where care is delivered (Part B)45% facility · 55% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”